Seminars in Oncology
Volume 34, Issue 5 , Pages 406-410 , October 2007

Screening and Prevention of Hereditary Gynecologic Cancers

  • Siobhan M. Kehoe

      Affiliations

    • Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.
    • ,
  • Noah D. Kauff

      Affiliations

    • Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.
    • Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
    • Corresponding Author InformationAddress correspondence to Noah D. Kauff, MD, Gynecology and Clinical Genetics Services, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Box 192, New York, NY 10021.

References 

  1. Rubin SC, Blackwood MA, Bandera C, et al: BRCA1, BRCA2 and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 178:670-677, 998
  2. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700–710
  3. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104:2807–2816
  4. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401–1408
  5. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families (The Breast Cancer Linkage Consortium). Am J Hum Genet. 1998;62:676–689
  6. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–1130
  7. King MC, Marks JH, Mandell JB New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643–646
  8. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283:2260–2265
  9. Ries LAG, Harkins D, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2003/, accessed August 4, 2006
  10. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002;20:1260–1268
  11. Liede A, Karlan BY, Baldwin RL, et al. Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol. 2002;20:1570–1577
  12. Hogg R, Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol. 2004;22:1315–1327
  13. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology–V.1.2006. Genetic/Familial High Risk Assessment: Breast and Ovarian Cancer. http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf
  14. Grimes DA, Economy KE. Primary prevention of gynecologic cancers. Am J Obstet Gynecol. 1995;172:227–235
  15. Whittemore AS, Belise RR, Pharoah PD, et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer. 2004;91:1911–1915
  16. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer (Hereditary Ovarian Cancer Clinical Study Group). N Engl J Med. 1998;339:424–428
  17. Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:235–240
  18. Narod SA, Dube MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002;94:1773–1779
  19. Liber AM. Ovarian cancer in a mother and five daughters. Arch Pathol. 1950;49:280–290
  20. Tobacman JK, Greene MH, Tucker MA, et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet. 1982;2:795–797
  21. Piver MS, Jishi MF, Tsukada Y, et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer (A report of the Gilda Radner Familial Ovarian Cancer Registry). Cancer. 1993;71:2751–2755
  22. Struewing JP, Watson P, Easton DF, et al. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr. 1995;17:33–35
  23. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609–1615
  24. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616–1622
  25. Rutter JL, Wacholder S, Chetrit A, et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: An Israeli population-based case-control study. J Natl Cancer Inst. 2003;95:1072–1078
  26. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: An international case-control study. J Clin Oncol. 2005;23:7491–7496
  27. Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: A prospective cohort study. Lancet Oncol. 2006;7:223–229
  28. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 2006;296:185–192
  29. Society of Gynecologic Oncologists. Clinical Practice Committee Statement on Prophylactic Salpingo-Oophorectomy. Gynecol Oncol. 2005;98:179–181
  30. Satagopan JM, Boyd J, Kauff ND, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res. 2002;8:3776–3781
  31. Kauff ND, Mitra M, Robson ME, et al. Risk of ovarian cancer in BRCA1 and BRCA2 mutation negative hereditary breast cancer families. J Natl Cancer Inst. 2005;97:1382–1384
  32. Muller A, Fishel R. Mismatch repair and the hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Invest. 2002;20:102–109
  33. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006;66:7810–7817
  34. Vasen HF, Winjen JT, Menko FH, et al. Cancer risk in patients with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology. 1996;110:1020–1027
  35. Aarnio M, Sankila R, Pakkula E, et al. Cancer risk in mutation carriers of DNA-mismatch repair genes. Int J Cancer. 1999;81:214–218
  36. Dunlop MG, Farrington SM, Carothers AD, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet. 1997;6:105–110
  37. Lu KH, Dinh M, Kohlmann W, et al. Gynecologic cancer as a “sentinel cancer” for women with the hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol. 2005;105:569–574
  38. Vasen HF, Mecklin JP, Khan PM, et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34:424–425
  39. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria hereditary nonpolyposis colorectal cancer ((HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC). Gastroenterology. 1999;116:1453–1456
  40. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: Meeting highlights and Bethesda guidelines. J Natl Cancer Inst. 1997;89:1758–1762
  41. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–268
  42. Guillem JG, Wood WC, Moley JF, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol. 2006;24:4642–4660
  43. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology—V.1.2007. Colorectal Cancer Screening. http://www.nccn.org/professionals/physician_gls/PDF/colorectal_screening.pdf
  44. Lindor NM, Peterson GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: A systemic review. JAMA. 2006;296:1507–1517
  45. Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829–834
  46. Dove-Edwin I, Boks D, Goff S, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer. 2002;94:1708–1712
  47. Rijcken F, Mourits M, Kleibeuker J, et al. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol. 2003;91:74–80
  48. Schmeler KM, Lynch HT, Chen L, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006;354:261–269
  49. Offit K, Kauff ND. Reducing the risk of gynecologic cancer in the Lynch syndrome. N Engl J Med. 2006;354:293–295

PII: S0093-7754(07)00141-8

doi: 10.1053/j.seminoncol.2007.07.004

Seminars in Oncology
Volume 34, Issue 5 , Pages 406-410 , October 2007

Article Tools